本帖最后由 老马 于 2013-3-13 13:43 编辑 8 F6 A! I8 [7 ?3 F3 @3 ^
' ?' q5 ~) } I# W健择（吉西他滨）+顺铂+阿瓦斯汀. i" j3 Z: d% u1 O# e: R C& q" f
Gemzar +Cisplatin + Avastin- p( `3 o; v5 r) \: n# L
http://annonc.oxfordjournals.org/content/21/9/1804.full8 [ N7 Z- @7 U5 j) F- v+ i3 p
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) / X# m) v6 o, o- g; B' Q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 0 w: F2 J8 {3 f3 U+ O6 b; A4 R" s
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 2 `% @, s, c. K9 w6 M; c
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 898)
/ V+ z3 Q' H" H4 o
华为网盘附件：
+ G O( Y& H$ I【华为网盘】ava.JPG; W. u0 r$ ^; w) p) U! M/ g" D2 f
|
显身卡
